共 50 条
- [34] Observational 24-week study to assess clinical response to upadacitinib posttrial in patients with moderate-to-severe atopic dermatitis JEADV CLINICAL PRACTICE, 2023, 2 (03): : 571 - 575
- [39] Baseline Serum Biomarkers Do Not Predict Dupilumab Treatment Response in AdultsWith Moderate-to-Severe Atopic Dermatitis JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 101 - 101